Same idea, different starting points
Both drugs use a step-up schedule for the same underlying reason: reduce the risk of side effects severe enough that someone stops. But the numbers themselves aren’t interchangeable, because the two drugs work through a different number of receptors and have different published dose ranges.
Receptor count
Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP and glucagon. That third receptor is the main mechanistic difference, and it’s part of why the two aren’t simply “the same schedule with different numbers”.
Comparing the published ranges
Tirzepatide’s approved range runs from a 2.5mg starting dose to a 15mg maximum, in 2.5mg steps. Retatrutide’s trial arms ran from a 2mg start to as high as 12mg, generally in 2mg or 4mg steps. Neither schedule is “faster” by design; the step count and hold length across both is broadly similar, four weeks being the common denominator.
Where people report differences
Community and trial-adjacent reporting on early side effects differs person to person more than it differs cleanly by drug, but the glucagon receptor’s role in retatrutide is sometimes associated with a distinct early adjustment period beyond typical GLP-1 nausea, tied to its effect on energy expenditure. This isn’t the same as one drug being harder to titrate than the other across the board.
Choosing between them isn’t just a titration question
The titration pace for either drug is similar enough that it shouldn’t be the deciding factor between them. Availability, published trial data for a specific goal, and how a person’s body has responded to GLP-1 drugs before all matter more than which one steps up in smaller increments.